Amy L. Billett, MD

Director of Safety and Quality, Division of Pediatric Hematology/Oncology

Institute Physician

Associate Professor of Pediatrics, Harvard Medical School
Office Phone: 617-632-5640
Appointment Phone: 888-733-4662 (new), 617-632-3270 (established)
Fax: 617-632-4811
Preferred Contact Method: office phone

General

Treatment Centers
Discipline
Pediatric Hematology/Oncology
Clinical Interests
Electronic health records, Global health, Lymphoma (Hodgkin and Non-Hodgkin), Management of nausea and vomiting, Patient safety, Quality improvement

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA  02215

Background

Board Certifications
Pediatric Hematology/Oncology, 2001
Fellowships
Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 1990
Residency
University of Washington Hospitals
Internships
Children's Hospital and Medical Center
Medical School
Harvard Medical School, 1984
Biography
Dr. Billett received her MD from Harvard Medical School in 1984. After completing a residency in pediatrics at the University of Washington Hospitals, she completed a fellowship in pediatric hematology-oncology at Children's Hospital Boston and Dana-Farber Cancer Institute and became a staff physician in the pediatric hematology/oncology program in 1990. She was the medical director of the inpatient oncology service at Children's Hospital 1995-2005.

Dr. Billett has participated in multiple projects involving improving systems of care, including development of a pediatric chemotherapy order entry system, implementation of the joint CH-DFCI pediatric electronic health record. She is currently the medical director for patient safety and quality in the pediatric hematology/oncology program, the leader of the pediatric lymphoma program, and an active clinician in the program.

She is a clinical faculty leader of the newly established national collaborative to reduce catheter-associated blood stream infections in pediatric hematology/oncology patients.
Research
Hodgkin's Disease in Children, CLABSI-reduction

Our program has been an active member of a small national consortium for clinical trials in pediatric Hodgkins since 1990. pediatric Hodgkin's disease. We currently have three open trials looking at improving/maintaining efficacy while minimizing long-term toxicity.Our center is a founding member of a national quality improvement collaborative started in 2009 to reduce catheter-associated blood stream infections in pediatric hematology-oncology patients. The focus of the collaborative is reliable implementation of best central line maintenance care.

Video: Meet Amy L. Bullett, MD

Appointments & Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Clinical Trials

Search our wide range of clinical trials, including novel therapies, immunotherapy and personalized therapy.callout bg

Harvard Medical Affiliate

HMS Callout FAD 

As a teaching affiliate of Harvard Medical School, our physicians are passing on their expertise to the next generation of pediatric hematologists and oncologists.